Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases

Hypertrophic Cardiomyopathy Clinical Trial

Official title: Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases

Status Recruiting

Clinical Trial Summary

The aim of this study is the identification of familial congenital arrhythmogenic disorders and their clinical follow-up.

Clinical Trial Description

Molecular genetic screening in patients with:

• supraventricular

• ventricular arrhythmia

• syncopes of unknown origin and/or suspicion of an arrhythmogenic origin

• family members of patients with sudden cardiac death and aborted sudden cardiac death

Examination of patients includes routine testing like electrocardiogram (ECG), sequential ECGs, exercise testing, invasive electrophysiological stimulation, cardiac magnetic resonance imaging, intravenous drug challenge for identification/exclusion of eg Brugada syndrome. Examples are patients with Long QT Syndrome, Short QT Syndrome, Brugada Syndrome, familial atrial fibrillation, WPW-syndrome, arrhythmias due to familial hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia. Blood samples are taken for further molecular genetic screening. ;

Study Design

Observational Model: Family-Based, Time Perspective: Prospective

Related Conditions & MeSH terms

• Arrhythmogenic Right Ventricular Dysplasia
• Cardiomyopathies
• Cardiomyopathy, Hypertrophic
• Hypertrophic Cardiomyopathy
• Hypertrophy
• Long QT Syndrome

• NCT number: NCT00221832
• Study type: Observational
• Source: Heidelberg University
• Contact: Christian Wolpert, MD
• Phone: +49-621-383-2206
• Email: christian.wolpert@med.ma.uni-heidelberg.de
• Status: Recruiting
• Phase: N/A
• Start date: October 2003
• Completion date: December 2011